Xarelto Lawsuit Time Is Running Out To File


As first trial dates in the class action suit against the drug manufacturing company of Xarelto are set, the window narrows to submit a claim for injury settlement.

On Sept. 17, Judge Eldon E. Fallon signed the case management order establishing bellwether trial choice dates for autumn 2016. The four trials will take place across Louisiana, Mississippi and Texas, and certainly will hear specific cases chosen to accelerate the litigation of the large number of suits now pending against Bayer Healthcare and Janssen Pharmaceuticals, makers of Xarelto.

Michael Goetz, a lawyer at the Sophisticated litigation group of Morgan & Morgan, is playing a leadership role in the multi-district litigation. He’s an associate of the plaintiff’s steering committee, composed of multiple lawyers to arrange plaintiff claims.

“Our plaintiffs have endured life-transforming or stopping harms as an outcome of the dangerous effects of the drug, and we’re steadfastly committed to bringing them justice,” Goetz said.

The Xarelto multi-district litigation was formed due to the increasing amount of cases against the defendant in December 2014. The cases, which all made similar accusations against the drug supplier, allege Xarelto causes uncontrollable and serious internal bleeding, in a few cases leading to death.

In addition, the suits says Xarelto makers failed to warn consumers and were conscious of these effects.

Xarelto side effects reads, “Xarelto can cause bleeding, which may be serious, and infrequently can lead to death.”

“All anticoagulants, or blood thinners, carry the danger of bleeding,” the defendant said. “The prescribing information for Xarelto has consistently warned of this danger.”

But, the plaintiffs allege that unlike conventional anticoagulants, whose effects could be reversed through common drugs like Vitamin K, Xarelto does not have any antidote.